Senolytic Therapeutics To Eliminate Senescent Cells And Enhance Aging And Cancer Treatments

Interests: Oncology

Published: February 27, 2025

Lead Inventor: Jing Chen

Targeted approach to remove aging, disease-related, or chemotherapy/immunotherapy-induced senescent cells while sparing healthy cells

Research in age-related diseases and cancer has increasingly highlighted the detrimental role of accumulated senescent cells. In both aging and therapeutic contexts, these cells contribute to tissue dysfunction and chronic inflammation, exacerbating conditions such as fibrosis, atherosclerosis, and overall organ decline. There is a growing need for advanced technologies that can address the underlying cellular mechanisms responsible for these pervasive health issues. Researchers and clinicians are actively seeking methods to improve patient outcomes by targeting the root causes of cellular aging, which in turn may alleviate clinical symptoms and improve long-term health.
Current approaches to manage cellular senescence and its sequelae face significant shortfalls. Conventional treatments often lack specificity, leading to collateral damage in healthy cells and unintended side effects. The limited efficacy of prevailing methods, combined with challenges in dosing and administration routes, has hindered progress in mitigating therapy-induced senescence and its associated complications. As a result, there remains an ongoing demand for more refined techniques that can selectively target dysfunctional cells without compromising normal tissue function, ultimately aiming to enhance treatment tolerability and effectiveness in complex age-related and cancer treatment scenarios.

Through systematic screening of numerous blood chemicals faculty inventor identified Vanadyl sulfate (VS) is a therapeutic agent that selectively eliminates senescent cells-including those from aging and therapy-induced sources- while sparing normal cells. The faculty inventor demonstrated in human fibroblast models and aged mice show that oral VS improves aging phenotypes, reduces serum markers such as urea, p16INK4a, and IL-6, and offers various administration routes, from oral and parenteral to topical and intranasal. Its dosing flexibility (0.01 mg/kg to 200 mg/kg) and formulation as dietary supplements or pharmaceuticals add to its adaptable features.
Moreover, VS shows promise when combined with chemotherapeutics and immunotherapies, enhancing treatment efficacy while reducing side effects. Its extensive potential in addressing aging-related ailments, fibrosis, atherosclerosis, and even enhancing cancer treatment underscores its innovative role in advancing senolytic therapeutic strategies.

Selective elimination of senescent cells while sparing normal cells, reducing age-related damage
Improvement in aging phenotypes and reduction of key biomarkers
Versatile administration options with flexible dosing, supporting both dietary supplement and pharmaceutical formats
Enhanced cancer treatment efficacy when used in combination with chemotherapeutics, radiotherapy, and immunotherapy